<DOC>
	<DOCNO>NCT00354341</DOCNO>
	<brief_summary>This study assess effect anemia correction NeoRecormon cardiac structure function patient early diabetic nephropathy . The anticipated time study treatment 1-2 year target sample size 100-500 individual .</brief_summary>
	<brief_title>( ACORD Study ) - A Study NeoRecormon ( Epoetin Beta ) Patients With Early Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; type 1 type 2 diabetes ; stable glycemic control &gt; =3 month ; diabetic nephropathy . woman pregnant , breastfeeding , unwilling use reliable contraceptive method ; previous treatment erythropoietin erythropoietic substance ; nondiabetic renal disease , nephrotic syndrome ; blood transfusion within 3 month prior enrollment ; administration investigational drug within 30 day precede study start , study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>